Contineum Therapeutics, Inc. 8-K

What Happened Contineum Therapeutics, Inc. (CTNM) held its 2026 Annual Meeting of Stockholders virtually on June 26, 2026. As of the April 27, 2026 record date there were 32,723,877 shares of Class A common stock outstanding and entitled to vote. Stockholders elected three Class II directors — Evert Schimmelpennink, Lori M. Lyons-Williams and Diego Miralles, M.D. — each to serve until the 2029 Annual Meeting (or until their successors are elected). Stockholders also ratified the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The 8-K was signed by CFO Peter Slover.

Key Details

• Record date and shares outstanding: 32,723,877 shares of Class A common stock (April 27, 2026).
• Director election votes:
  • Evert Schimmelpennink — For: 21,773,559; Withheld: 131,384; Broker non-votes: 6,133,812.
  • Lori M. Lyons-Williams — For: 20,593,715; Withheld: 1,311,228; Broker non-votes: 6,133,812.
  • Diego Miralles, M.D. — For: 21,673,187; Withheld: 231,756; Broker non-votes: 6,133,812.
• Auditor ratification: Ernst & Young LLP ratified — For: 28,021,047; Against: 16,104; Withheld: 1,604.

Why It Matters These voting results confirm the company’s board composition and continuation of its external audit relationship, both key governance items investors watch for oversight and continuity. The presence of 6,133,812 broker non-votes on the director elections indicates a significant portion of outstanding shares were not voted by brokers on those routine/non-routine items; however, the listed nominees received a clear majority of votes cast. Ratification of Ernst & Young ensures the company’s auditor is in place for the 2026 fiscal year.